Innate Pharma S.A.
Innate Pharma S.A. (NASDAQ: IPHA) is trading at $1.63, about ₹157 at today's USD/INR rate, as of 30 Sep 2026, 4:00 PM ET, up 1.88% today. Indian residents can buy Innate Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$1.61
Today's high
$1.66
52 week low
$1.17
52 week high
$2.71
IPHA opened at $1.61, closed previously at $1.60, and has traded between $1.17 and $2.71 over the past 52 weeks.
About
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Key statistics
Avg. volume
117.69K
Market cap
$153.06M
P/E Ratio
-2.75
Price-to-sales ratio
126.35
Enterprise value
€127.66M
Free cash flow yield
-26.21%
Debt-to-equity ratio
-0.50
Return on equity
226.68%
ROIC
-153.25%
Beta
0.88
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
€2.79M
Earnings per share
-€0.53
Free cash flow
-€34.91M
Net profit margin
-4554.32%
Gross margin
1770.35%
EBITDA
-€43.65M
Revenue growth
-77.92%
Similar securities
This is not an investment recommendation
How to buy Innate Pharma from India
Indian residents can buy Innate Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Innate Pharma and place an order
Find Innate Pharma by name or by its ticker, IPHA, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Innate Pharma trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Innate Pharma position in USD and INR. Innate Pharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Innate Pharma from India
Trading and taxes when buying Innate Pharma from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneInnate Pharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Innate Pharma stock?
Yes. Innate Pharma (IPHA) has been listed on NASDAQ since 2019, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Innate Pharma share cost in rupees?
One Innate Pharma share is $1.63 — about ₹157 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Innate Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Innate Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Innate Pharma?
Yes. One Innate Pharma share is $1.63, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Innate Pharma.
How are gains on Innate Pharma shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Innate Pharma price. Paasa issues a capital-gains statement for your return.
Does Innate Pharma pay a dividend?
No. Innate Pharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Innate Pharma from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is Innate Pharma a United States company, and does that change how it is taxed?
Innate Pharma trades on NASDAQ in US dollars, but the company is domiciled in France. Innate Pharma trades as an American Depositary Receipt rather than an ordinary share. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.
Do I have to declare Innate Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Innate Pharma holding, its cost and its closing value.
How do I sell Innate Pharma and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.